Dimensional Fund Advisors LP Affimed N.V. Transaction History

Dimensional Fund Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$0.32 - $0.62 $30,909 - $59,886	-96,591 Reduced 87.88%	13,323 $8,000
Q3 2023 Nov 09, 2023	SELL	$0.46 - $0.65 $1,742 - $2,462	-3,788 Reduced 3.33%	109,914 $52,000
Q2 2023 Aug 09, 2023	SELL	$0.57 - $1.08 $7,709 - $14,608	-13,526 Reduced 10.63%	113,702 $68,000
Q1 2023 May 12, 2023	SELL	$0.66 - $1.29 $73,114 - $142,906	-110,780 Reduced 46.54%	127,228 $95,000
Q4 2022 Feb 09, 2023	SELL	$1.1 - $2.45 $122,548 - $272,949	-111,408 Reduced 31.88%	238,008 $295,000
Q3 2022 Nov 10, 2022	BUY	$1.96 - $3.32 $58,074 - $98,371	29,630 Added 9.27%	349,416 $720,000
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $349,051 - $747,307	153,767 Added 92.62%	319,786 $886,000
Q1 2022 May 13, 2022	BUY	$3.69 - $5.65 $612,610 - $938,007	166,019 New	166,019 $726,000
Q1 2021 May 14, 2021	SELL	$5.12 - $8.48 $1.72 Million - $2.84 Million	-335,115 Closed	0 $0
Q4 2020 Feb 25, 2021	BUY	$3.16 - $7.03 $1.06 Million - $2.36 Million	335,115 New	335,115 $1.95 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.